Market revenue in 2022 | USD 6.5 million |
Market revenue in 2030 | USD 20.5 million |
Growth rate | 15.5% (CAGR from 2022 to 2030) |
Largest segment | Cholinesterase inhibitors |
Fastest growing segment | Combination Drugs |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs |
Key market players worldwide | Eisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 52.31% in 2022. Horizon Databook has segmented the Argentina alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs covering the revenue growth of each sub-segment from 2018 to 2030.
In Argentina, AD is the fifth leading cause of death, and there are around 300,000 people in the country living with the disease. Alzheimer’s therapeutics market is expected to grow at a significant rate owing to increasing prevalence of dementia, government awareness programs, and high unmet medical need in the country.
In Argentina, Alzheimer's Disease Neuroimaging Initiative (Arg-ADNI) launched the first South American initiative to acquire AD data comparable to other data sources. The goal of Arg-ADNI is developing biomarkers for AD to identify possible predictive measures of the disease progression.
A startup from National Scientific and Technical Research Council has developed a technology called Eye Tracking, which promises to detect Alzheimer’s 10 years ahead of time. The company has been selected by the Luxembourg government to expedite its growth and commercialize the technology in the European market.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina alzheimers therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Argentina alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account